ArticleESMO open2021

High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.

B Gülave et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.